<DOC>
	<DOCNO>NCT02695940</DOCNO>
	<brief_summary>This phase 2a trial test twice daily administration LEO 124249 ointment 30 mg/g treatment mild moderate inverse psoriasis . Patients treat 6 week , efficacy safety compare treatment LEO 124249 ointment vehicle .</brief_summary>
	<brief_title>Trial Twice Daily Application LEO 124249 Ointment 30 mg/g Treatment Mild Moderate Inverse Psoriasis</brief_title>
	<detailed_description>Single country , Multi-center , prospective , randomised , double-blind , 2 arm parallel-group , vehicle-controlled , 6 week , phase 2a trial subject mild moderate inverse psoriasis . LEO 124249 ointment 30 mg/g LEO 124249 ointment vehicle treatment compare regard efficacy safety .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Provision sign date informed consent prior trial specific procedure Male female subject 18 75 year A diagnosis stable mild moderate inverse psoriasis ( i.e . axilla , infra intermammary , genital , scrotum , abdominal retroauricular fold ; intergluteal cleft perianal skin , addition neck skin fold ) . Mild moderate define least score 1 individual sign thickness redness , total TSS score least 5 . The total treatment area 4 % BSA ( 720 cm2 ) . Subjects must history psoriasis , psoriasis , present characteristic psoriasis leasons elsewhere body ( include scalp ) Visit 1 ( Screening ) Stable inverse psoriasis base TSS evaluate Visit 1 ( Screening ) Visit 2 ( Start treatment ) , must differ 1 point single clinical sign score ( redness , scale thickness ) Except inverse psoriasis , overall good health include well control disease ( e.g . hypertension , diabetes , thyroid disease ) determine medical history , physical examination , electrocardiogram ( ECG ) , vital sign ( blood pressure , heart rate body temperature ) clinical laboratory evaluation Female subject breastfeed pregnant Severe chronic inverse psoriasis , psoriasis body ( &gt; 30 % BSA ) Current diagnosis acute guttate , erythrodermic , exfoliative pustular psoriasis Signs viral ( e.g . herpes varicella ) lesion skin , sign clinically active fungal bacterial infection inverse psoriasis area , judge investigator Use biological therapy ( marketed/not market ) possible effect inverse psoriasis within 4 week ( etanercept ) , 8 week ( adalimumab , alefacept , infliximab ) , 16 week ( ustekinumab , secukinumab ) 4 weeks/5 halflives ( whichever longer ) experimental biological product prior Visit 2 ( Start treatment ) Use systemic treatment ( marketed/nonmarketed ) , biologics , potential effect inverse psoriasis ( e.g. , corticosteroid , retinoids , dimethylfumarate , cyclosporine , azathioprine methotrexate , immunosuppressant ) within 6 week prior Visit 2 ( Start treatment ) ( inhale intranasal steroid correspond 1 mg prednisone asthma rhinitis may use ) Use potent topical corticosteroid ( WHO group IV ) treatment psoriasis body and/or scalp within 4 week prior Visit 2 ( Start treatment ) Use topical medication treatment inverse psoriasis : WHO group IIII corticosteroid , retinoids , vitamin D analogue , immunomodulators ( e.g . macrolides , calcineurin ) , anthracen derivative , tar , salicylic acid within 2 week prior Visit 2 ( Start treatment ) Exposure phototherapy ( PUVA , UVA , UVB , Grenz Ray therapy ) within 4 week prior Visit 2 ( Start treatment ) Subjects positive HBV score antibody , HBsAg , antiHCV antiHIV test Visit 1 ( Screening ) Subjects history immunocompromising disease ( e.g. , lymphoma , HIV , WiskottAldrich Syndrome ) Any current dermatological disorder ( e.g . serborrhic dermatitis , contact dermatitis , cutaneous mycosis ) may confound evaluation inverse psoriasis Known malignancy ( cervical carcinoma situ , basal cell squamous cell carcinoma ) within 5 year Visit 1 ( Screening )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>